Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06629714 | Impact of Pretreatment Emotional Distress on Survival and the Predictive Role of Peripheral Biomarkers in Immunotherapy Response Among Gastroesophageal and Lung Cancer Patients | completed | — | 196 | Anhui Medical UniversityOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT02442349 | Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific(AURA17) | completed | Phase 2 | 171 | AstraZenecaINDUSTRY | 3 | Jan 9, 2026 |
| clinicaltrials |
| NCT07141563 | A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC | completed | — | 70 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT02998528 | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)(CheckMate 816) | completed | Phase 3 | 505 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 6, 2026 | clinicaltrials |
| NCT05054725 | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | completed | Phase 2 | 47 | Revolution Medicines, Inc.INDUSTRY | 10 | Jan 6, 2026 | clinicaltrials |
| NCT06029127 | A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer | completed | Phase 2 | 35 | BeiGeneINDUSTRY | 2 | Jan 5, 2026 | clinicaltrials |
| NCT07316309 | CXCR4 PET/CT for Predicting Outcome in Limited-Stage Small Cell Lung Cancer | completed | — | 33 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT02473133 | Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC(RTEP7) | completed | Phase 2 | 158 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT02821936 | Parametric Imaging in Positron Emission Tomography for Patient With Lung Cancer(PARAPET) | completed | N/A | 40 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03832348 | Dynamics of 18-FDG Uptake in Stage III/IV Non Small Cell Lung Cancer During First Line Pembrolizumab Treatment(iTEP1) | completed | N/A | 40 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04224337 | Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma | completed | Phase 2 | 16 | Seoul National University HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04490564 | Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma | completed | — | 135 | Pharmassist LtdINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04045496 | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 40 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT03810807 | Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer | completed | Phase 1 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04589013 | Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer(PRINCE) | completed | — | 106 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT00213798 | Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients | completed | N/A | 200 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04471428 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy(CONTACT-01) | completed | Phase 3 | 366 | Hoffmann-La RocheINDUSTRY | 15 | Dec 22, 2025 | clinicaltrials |
| NCT05465343 | Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE) | completed | Phase 2 | 24 | Peking Union Medical CollegeOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04965090 | A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03215706 | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC(CheckMate 9LA) | completed | Phase 3 | 719 | Bristol-Myers SquibbINDUSTRY | 19 | Dec 17, 2025 | clinicaltrials |
| NCT02314364 | A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC | completed | Phase 2 | 27 | Massachusetts General HospitalOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT02621398 | Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer | completed | Phase 1 | 23 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05001347 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | completed | Phase 2 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 6 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT02592577 | MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC | completed | Phase 1 | 28 | AdaptimmuneINDUSTRY | 4 | Dec 9, 2025 | clinicaltrials |
| NCT04063163 | A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC | completed | Phase 3 | 585 | Shanghai Henlius BiotechINDUSTRY | 5 | Dec 9, 2025 | clinicaltrials |
| NCT07271446 | An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer | completed | Phase 1 | 8 | Precision Biotech Taiwan Corp.INDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT03177291 | Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC | completed | Phase 1 | 48 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03735121 | A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 3 | 438 | Hoffmann-La RocheINDUSTRY | 23 | Dec 5, 2025 | clinicaltrials |
| NCT07267247 | Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer | completed | — | 100 | Taichung Veterans General HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03836066 | Atezolizumab Plus Bevacizumab in First Line NSCLC Patients(TELMA) | completed | Phase 2 | 41 | Fundación GECPOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03926260 | Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA(ELUCID) | completed | N/A | 100 | Centre Hospitalier Departemental VendeeOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05440916 | Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer(PRIMM) | completed | Phase 2 | 50 | University Medical Centre MariborOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07250360 | Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC | completed | — | 2,072 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Nov 26, 2025 | clinicaltrials |
| NCT02639026 | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | completed | Phase 1 | 53 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03132532 | Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03307785 | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | completed | Phase 1 | 60 | Tesaro, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07243899 | Multimodal Model Predicts Treatment Efficacy and CIP Risk in Advanced NSCLC With Immunotherapy and Chemotherapy | completed | — | 3,000 | Shanghai Zhongshan HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04644237 | Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)(DESTINY-LUNG02) | completed | Phase 2 | 152 | Daiichi SankyoINDUSTRY | 10 | Nov 21, 2025 | clinicaltrials |
| NCT05339022 | Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial | completed | N/A | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05668585 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | completed | Phase 1 | 89 | C4 Therapeutics, Inc.INDUSTRY | 5 | Nov 21, 2025 | clinicaltrials |
| NCT02197234 | Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC | completed | Phase 1 | 52 | AstraZenecaINDUSTRY | 5 | Nov 20, 2025 | clinicaltrials |
| NCT01186861 | Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy | completed | Phase 2 | 205 | Astellas Pharma IncINDUSTRY | 9 | Nov 18, 2025 | clinicaltrials |
| NCT01221077 | Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene | completed | Phase 2 | 88 | Astellas Pharma IncINDUSTRY | 6 | Nov 18, 2025 | clinicaltrials |
| NCT04895579 | Lung Cancer With Copanlisib and Durvalumab(LCD) | completed | Phase 1 | 11 | Zhonglin HaoOTHER | 1 | Nov 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 13, 2026source: clinicaltrials